Literature DB >> 15996659

A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein.

Oscar Moran1, Olga Zegarra-Moran.   

Abstract

The CFTR, encoded by the gene mutated in cystic fibrosis (CF) patients, is responsible for cAMP dependent chloride transport in epithelia. Substances that activate CFTR have been suggested as possible CF therapy. Most substances investigated so far exert a dual effect on the CFTR: low concentrations stimulate CFTR, whereas higher concentrations inhibit CFTR. Besides, the CFTR phosphorylation level determines the apparent affinity of the drug. We have studied the properties of genistein, the well known CFTR potentiator, by measuring apical membrane current on epithelia formed by cells stably transfected with CFTR and stimulated with different concentrations of CPTcAMP. We propose a quantitative model to describe the activatory and inhibitory effect of genistein, accounting also for the cAMP dependent activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996659     DOI: 10.1016/j.febslet.2005.06.026

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  15 in total

1.  Modulation of cystic fibrosis transmembrane conductance regulator (CFTR) activity and genistein binding by cytosolic pH.

Authors:  Raffaella Melani; Valeria Tomati; Luis J V Galietta; Olga Zegarra-Moran
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

2.  Resveratrol has salutary effects on mucociliary transport and inflammation in sinonasal epithelium.

Authors:  Nathan S Alexander; Neal Hatch; Shaoyan Zhang; Daniel Skinner; James Fortenberry; Eric J Sorscher; Bradford A Woodworth
Journal:  Laryngoscope       Date:  2011-04-07       Impact factor: 3.325

3.  Stimulation of murine intestinal secretion by daily genistein injections: gender-dependent differences.

Authors:  Layla Al-Nakkash; Lyn Batia; Minoti Bhakta; Amity Peterson; Nathan Hale; Ryan Skinner; Steven Sears; Jesse Jensen
Journal:  Cell Physiol Biochem       Date:  2011-08-16

4.  Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency.

Authors:  Bradford A Woodworth
Journal:  Laryngoscope       Date:  2015-05-06       Impact factor: 3.325

5.  Chlorogenic Acid Activates CFTR-Mediated Cl- Secretion in Mice and Humans: Therapeutic Implications for Chronic Rhinosinusitis.

Authors:  Elisa A Illing; Do-Yeon Cho; Shaoyan Zhang; Daniel F Skinner; Quinn A Dunlap; Eric J Sorscher; Bradford A Woodworth
Journal:  Otolaryngol Head Neck Surg       Date:  2015-05-27       Impact factor: 3.497

6.  Characterization of a 7,8-benzoflavone double effect on CFTR Cl(-) channel activity.

Authors:  Loretta Ferrera; Chiara Pincin; Oscar Moran
Journal:  J Membr Biol       Date:  2007-09-18       Impact factor: 1.843

7.  ATP-driven Rad50 conformations regulate DNA tethering, end resection, and ATM checkpoint signaling.

Authors:  Rajashree A Deshpande; Gareth J Williams; Oliver Limbo; R Scott Williams; Jeff Kuhnlein; Ji-Hoon Lee; Scott Classen; Grant Guenther; Paul Russell; John A Tainer; Tanya T Paull
Journal:  EMBO J       Date:  2014-02-03       Impact factor: 11.598

8.  Potentiators exert distinct effects on human, murine, and Xenopus CFTR.

Authors:  Guiying Cui; Netaly Khazanov; Brandon B Stauffer; Daniel T Infield; Barry R Imhoff; Hanoch Senderowitz; Nael A McCarty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2016-06-10       Impact factor: 5.464

9.  How Phosphorylation and ATPase Activity Regulate Anion Flux though the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR).

Authors:  Matthias Zwick; Cinzia Esposito; Manuel Hellstern; Anna Seelig
Journal:  J Biol Chem       Date:  2016-05-12       Impact factor: 5.157

10.  Calpain inhibition promotes the rescue of F(508)del-CFTR in PBMC from cystic fibrosis patients.

Authors:  Monica Averna; Marco Pedrazzi; Laura Minicucci; Roberta De Tullio; Federico Cresta; Franca Salamino; Sandro Pontremoli; Edon Melloni
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.